Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration

doi:10.4292/wjgpt.v7.i2.294

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5983)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

417

WORD

375

HTML

3179

Figures (1-6)

115

Tables (1-4)

130

Sum=4216

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

735

Download

1032

Sum=1767

May 6, 2016 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294

Full Size Figure Download Figure

Figure 1 Forrest plot showing infection rates as fraction of the sample size in cohorts treated with sacral neurostimulation for fecal incontinence.

Citation: Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
URL: https://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v7.i2.294